Table 4.

Example of risk assessment matrix for drug nanocrystals analyzing the impact of critical material attributes (CMAs) and critical process parameters (CPPs) on product attributes: case study for drug nanocrystals. Modified from [73].

CQAs	Risk Assessment Matrix
	CMAs			CPPs
	Surfactant Type	Surfactant Concentration	Drug Amount	Milling Time	Milling Speed	Bead Size
Particle size	Medium	Medium	Medium	High	High	High
PDI	Medium	High	Medium	High	High	High
Zeta potential	High	High	Medium	Medium	Medium	Medium
Drug content	Low	Low	Low	low	Low	Low
Drug release	Medium	Medium	Medium	High	High	High